A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity |
Kim, KyeongJin
(Department of Biomedical Sciences, College of Medicine, Inha University)
Yang, Wen-Hao (Graduate Institute of Biomedical Sciences, China Medical University) Jung, Youn-Sang (Department of Life Science, Chung-Ang University) Cha, Jong-ho (Department of Biomedical Sciences, College of Medicine, Inha University) |
1 | Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97-103 DOI |
2 | Matson V, Fessler J, Bao R et al (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104-108 DOI |
3 | Routy B, Le Chatelier E, Derosa L et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91-97 DOI |
4 | de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V et al (2017) Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care 40, 54-62 DOI |
5 | Feng W, Ao H and Peng C (2018) Gut Microbiota, Short-Chain Fatty Acids, and Herbal Medicines. Front Pharmacol 9, 1354 DOI |
6 | Parada Venegas D, De la Fuente MK, Landskron G et al (2019) Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol 10, 277 DOI |
7 | Waldman AD, Fritz JM and Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20, 1-18 DOI |
8 | Duan Q, Zhang H, Zheng J and Zhang L (2020) Turning Cold into Hot: Firing up the Tumor Microenvironment. Trends Cancer 6, 605-618 DOI |
9 | Bonaventura P, Shekarian T, Alcazer V et al (2019) Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front Immunol 10, 168 DOI |
10 | Quail DF and Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19, 1423-1437 DOI |
11 | Kambayashi T and Laufer TM (2014) Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell? Nat Rev Immunol 14, 719-730 DOI |
12 | Hagemann T, Balkwill F and Lawrence T (2007) Inflammation and cancer: a double-edged sword. Cancer Cell 12, 300-301 DOI |
13 | Zitvogel L, Pietrocola F and Kroemer G (2017) Nutrition, inflammation and cancer. Nat Immunol 18, 843-850 DOI |
14 | Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4, 11-22 DOI |
15 | Poh AR and Ernst M (2018) Targeting Macrophages in Cancer: From Bench to Bedside. Front Oncol 8, 49 DOI |
16 | Landskron G, De la Fuente M, Thuwajit P, Thuwajit C and Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014, 149185 DOI |
17 | Gajewski TF, Schreiber H and Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14, 1014-1022 DOI |
18 | Wang M, Zhao J, Zhang L et al (2017) Role of tumor microenvironment in tumorigenesis. J Cancer 8, 761-773 DOI |
19 | D'Elia RV, Harrison K, Oyston PC, Lukaszewski RA and Clark GC (2013) Targeting the "cytokine storm" for therapeutic benefit. Clin Vaccine Immunol 20, 319-327 DOI |
20 | Kumar V, Patel S, Tcyganov E and Gabrilovich DI (2016) The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol 37, 208-220 DOI |
21 | Triggle CR and Ding H (2014) Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis 5, 245-268 DOI |
22 | Hanson EM, Clements VK, Sinha P, Ilkovitch D and Ostrand-Rosenberg S (2009) Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 183, 937-944 DOI |
23 | Crusz SM and Balkwill FR (2015) Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 12, 584-596 DOI |
24 | Brasky TM, Potter JD, Kristal AR et al (2012) Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control 23, 431-444 DOI |
25 | Liu Y, Chen JQ, Xie L et al (2014) Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med 12, 55 DOI |
26 | Nath N, Khan M, Paintlia MK, Singh I, Hoda MN and Giri S (2009) Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol 182, 8005-8014 DOI |
27 | Lund SS, Tarnow L, Stehouwer CD et al (2008) Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 158, 631-641 DOI |
28 | Kelly B, Tannahill GM, Murphy MP and O'Neill LA (2015) Metformin Inhibits the Production of Reactive Oxygen Species from NADH:Ubiquinone Oxidoreductase to Limit Induction of Interleukin-1beta (IL-1beta) and Boosts Interleukin- 10 (IL-10) in Lipopolysaccharide (LPS)-activated Macrophages. J Biol Chem 290, 20348-20359 DOI |
29 | Huang NL, Chiang SH, Hsueh CH, Liang YJ, Chen YJ and Lai LP (2009) Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int J Cardiol 134, 169-175 DOI |
30 | Ersoy C, Kiyici S, Budak F et al (2008) The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract 81, 56-60 DOI |
31 | Andrzejewski S, Siegel PM and St-Pierre J (2018) Metabolic Profiles Associated With Metformin Efficacy in Cancer. Front Endocrinol (Lausanne) 9, 372 DOI |
32 | Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M and Andreelli F (2012) Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122, 253-270 DOI |
33 | Aljofan M and Riethmacher D (2019) Anticancer activity of metformin: a systematic review of the literature. Future Sci OA 5, FSO410 |
34 | Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67, 10804-10812 DOI |
35 | Tseng HW, Li SC and Tsai KW (2019) Metformin Treatment Suppresses Melanoma Cell Growth and Motility Through Modulation of microRNA Expression. Cancers (Basel) 11, 209 DOI |
36 | Cha JH, Yang WH, Xia W et al (2018) Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell 71, 606-620 e607 DOI |
37 | Deng XS, Wang S, Deng A et al (2012) Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 11, 367-376 DOI |
38 | Feng Y, Ke C, Tang Q et al (2014) Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis 5, e1088 DOI |
39 | Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E and Udono H (2015) Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A 112, 1809-1814 DOI |
40 | Garcia EY (1950) Flumamine, a new synthetic analgesic and anti-flu drug. J Philipp Med Assoc 26, 287-293 |
41 | Zhang Z, Li F, Tian Y et al (2020) Metformin Enhances the Antitumor Activity of CD8(+) T Lymphocytes via the AMPKmiR-107-Eomes-PD-1 Pathway. J Immunol 204, 2575-2588 DOI |
42 | Paul S and Lal G (2017) The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. Front Immunol 8, 1124 DOI |
43 | Irons BK and Minze MG (2014) Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes Metab Syndr Obes 7, 15-24 DOI |
44 | Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305 DOI |
45 | Cha JH, Chan LC, Song MS and Hung MC (2019) New Approaches on Cancer Immunotherapy. Cold Spring Harb Perspect Med 10, a036863 |
46 | Del Barco S, Vazquez-Martin A, Cufi S et al (2011) Metformin: multi-faceted protection against cancer. Oncotarget 2, 896-917 DOI |
47 | Basu AK (2018) DNA Damage, Mutagenesis and Cancer. Int J Mol Sci 19, 970 DOI |
48 | Hyndman IJ (2016) Review: the Contribution of both Nature and Nurture to Carcinogenesis and Progression in Solid Tumours. Cancer Microenviron 9, 63-69 DOI |
49 | Mittal D, Gubin MM, Schreiber RD and Smyth MJ (2014) New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol 27, 16-25 DOI |
50 | Reeves E and James E (2017) Antigen processing and immune regulation in the response to tumours. Immunology 150, 16-24 DOI |
51 | Kim R, Emi M and Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121, 1-14 DOI |
52 | de Charette M, Marabelle A and Houot R (2016) Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy? Eur J Cancer 68, 134-147 DOI |
53 | Halenius A, Gerke C and Hengel H (2015) Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets-but how many arrows in the quiver? Cell Mol Immunol 12, 139-153 DOI |
54 | Kochan G, Escors D, Breckpot K and Guerrero-Setas D (2013) Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology 2, e26491 DOI |
55 | Balkwill FR, Capasso M and Hagemann T (2012) The tumor microenvironment at a glance. J Cell Sci 125, 5591-5596 DOI |
56 | Brown JM (1999) The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59, 5863-5870 |
57 | Wang JC, Sun X, Ma Q et al (2018) Metformin's antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization. J Cell Mol Med 22, 3825-3836 DOI |
58 | Qin G, Lian J, Huang L et al (2018) Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. Oncoimmunology 7, e1442167 DOI |
59 | Semenza GL (2016) The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochim Biophys Acta 1863, 382-391 DOI |
60 | Eales KL, Hollinshead KE and Tennant DA (2016) Hypoxia and metabolic adaptation of cancer cells. Oncogenesis 5, e190 DOI |
61 | Weidemann A and Johnson RS (2008) Biology of HIF-1alpha. Cell Death Differ 15, 621-627 DOI |
62 | Subarsky P and Hill RP (2003) The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 20, 237-250 DOI |
63 | Noman MZ, Messai Y, Carre T et al (2011) Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit Rev Immunol 31, 357-377 DOI |
64 | Clambey ET, McNamee EN, Westrich JA et al (2012) Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci U S A 109, E2784-2793 DOI |
65 | Mancino A, Schioppa T, Larghi P et al (2008) Divergent effects of hypoxia on dendritic cell functions. Blood 112, 3723-3734 DOI |
66 | Guimaraes TA, Farias LC, Santos ES et al (2016) Metformin increases PDH and suppresses HIF-1alpha under hypoxic conditions and induces cell death in oral squamous cell carcinoma. Oncotarget 7, 55057-55068 DOI |
67 | Vuillefroy de Silly R, Dietrich PY and Walker PR (2016) Hypoxia and antitumor CD8+ T cells: An incompatible alliance? Oncoimmunology 5, e1232236 DOI |
68 | Wang JC, Li GY, Li PP et al (2017) Suppression of hypoxia-induced excessive angiogenesis by metformin via elevating tumor blood perfusion. Oncotarget 8, 73892-73904 DOI |
69 | Zhou X, Chen J, Yi G et al (2016) Metformin suppresses hypoxia-induced stabilization of HIF-1alpha through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget 7, 873-884 DOI |
70 | Scharping NE, Menk AV, Whetstone RD, Zeng X and Delgoffe GM (2017) Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunol Res 5, 9-16 DOI |
71 | Thompson RH, Gillett MD, Cheville JC et al (2004) Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 101, 17174-17179 DOI |
72 | Zhang M, Li G, Wang Y et al (2017) PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep 7, 10255 DOI |
73 | Brody R, Zhang Y, Ballas M et al (2017) PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer 112, 200-215 DOI |
74 | Li J, Wang P and Xu Y (2017) Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and metaanalysis. PLoS One 12, e0179536 DOI |
75 | Han Y, Li CW, Hsu JM et al (2019) Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer. Am J Cancer Res 9, 800-815 |
76 | Schildberg FA, Klein SR, Freeman GJ and Sharpe AH (2016) Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 44, 955-972 DOI |
77 | Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12, 252-264 DOI |
78 | Verdura S, Cuyas E, Martin-Castillo B and Menendez JA (2019) Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. Oncoimmunology 8, e1633235 DOI |
79 | Garner H and de Visser KE (2020) Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nat Rev Immunol 20, 483-497 DOI |
80 | Voss K, Larsen SE and Snow AL (2017) Metabolic reprogramming and apoptosis sensitivity: Defining the contours of a T cell response. Cancer Lett 408, 190-196 DOI |
81 | Burns JS and Manda G (2017) Metabolic Pathways of the Warburg Effect in Health and Disease: Perspectives of Choice, Chain or Chance. Int J Mol Sci 18, 2755 DOI |
82 | Almeida L, Lochner M, Berod L and Sparwasser T (2016) Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol 28, 514-524 DOI |
83 | Afonso J, Santos LL, Longatto-Filho A and Baltazar F (2020) Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. Nat Rev Urol 17, 77-106 DOI |
84 | Garza-Lombo C, Schroder A, Reyes-Reyes EM and Franco R (2018) mTOR/AMPK signaling in the brain: Cell metabolism, proteostasis and survival. Curr Opin Toxicol 8, 102-110 DOI |
85 | Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA and Kedl RM (2013) T cell responses: naive to memory and everything in between. Adv Physiol Educ 37, 273-283 DOI |
86 | Blagih J, Coulombe F, Vincent EE et al (2015) The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42, 41-54 DOI |
87 | Rao E, Zhang Y, Zhu G et al (2015) Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death. Oncotarget 6, 7944-7958 DOI |
88 | Pollizzi KN, Patel CH, Sun IH et al (2015) mTORC1 and mTORC2 selectively regulate CD8(+) T cell differentiation. J Clin Invest 125, 2090-2108 DOI |
89 | van der Windt GJ and Pearce EL (2012) Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev 249, 27-42 DOI |
90 | Rolf J, Zarrouk M, Finlay DK, Foretz M, Viollet B and Cantrell DA (2013) AMPKalpha1: a glucose sensor that controls CD8 T-cell memory. Eur J Immunol 43, 889-896 DOI |
91 | Araki K, Turner AP, Shaffer VO et al (2009) mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108-112 DOI |
92 | Durack J and Lynch SV (2019) The gut microbiome Relationships with disease and opportunities for therapy. J Exp Med 216, 20-40 DOI |
93 | Xu H, Liu M, Cao J et al (2019) The Dynamic Interplay between the Gut Microbiota and Autoimmune Diseases. J Immunol Res 2019, 7546047 |
94 | Balakrishnan B and Taneja V (2018) Microbial modulation of the gut microbiome for treating autoimmune diseases. Expert Rev Gastroenterol Hepatol 12, 985-996 DOI |